

Development And Evaluation of Atorvastatin Calcium Nanovesicular Niosomal Gel for The Treatment of Periodontitis [†]

Nidhi S. Kate ^{1,*}, Bhushan R. Rane ^{1,*} and Ashish S. Jain ¹

¹ Department of Pharmaceutics, Shri D.D. Vispute, College of Pharmacy & Research Center, New Panvel 410206; email1@email.com

* Correspondence: nidhikate27@gmail.com (N.S.K.); rane7dec@gmail.com (B.R.R.); Tel.: +91-9702671051 (N.S.K.); +91-9421534437 (B.R.R.)

[†] Presented at the 4th International Electronic Conference on Applied Sciences, place, 27 October–10 November 2023; Available online: <https://asec2023.sciforum.net/>.

Abstract: Nowadays, smoking or tobacco-related habits (chewing tobacco) is recognized as the most frequent environmental risk factor for periodontal disorders. Atorvastatin Calcium (ATV) is a well-known lipid-lowering drug, but recent studies have discussed its pleiotropic effects, such as anti-inflammatory, anti-bacterial, etc. This anti-inflammatory effect can be studied as an adjunct for Scaling and Root planning (a non-surgical process to remove dental tartar and smooth root surfaces) for periodontics problems. The goal of the study is to formulate and evaluate ATV-niosomes, introduce them in a gel-based formulation by utilizing an appropriate gelling agent, and evaluate them for various parameters. The niosomal vesicles were prepared by the Thin-film hydration method. Gel was prepared using the dispersion method, and an in-vitro drug release study was conducted using a Franz-diffusion cell. According to the results evaluated, ATV niosomal gels loaded with different concentrations of Carbopol 934 were effectively produced utilizing ATV-niosomes that were formulated by the Thin-Film Hydration process using Cholesterol and Span 60. The ATV-niosomes showed the highest entrapment efficiency, up to 84%, and the zeta potential (−18 mV) and PDI (0.106) showed stable and homogenous behavior of the vesicles formed. The performance of the optimized gel containing 1% Carbopol 934 showed in-vitro release of up to 8 h following Zero Order release. The gel also proved to have antimicrobial activity against *S. aureus* and *P. aeruginosa*. Therefore, we conclude that 1% Carbopol 934 gel comprising ATV-niosomes showed a prolonged effect compared to plain ATV and can effectively work to improve the periodontal condition as an adjunct to Scaling and Root planning.

Citation: Kate, N.S.; Rane, B.R.; Jain, A.S. Development And Evaluation of Atorvastatin Calcium Nanovesicular Niosomal Gel for The Treatment of Periodontitis. *Eng. Proc.* **2023**, *52*, x. <https://doi.org/10.3390/xxxxx>

Keywords: niosomes; atorvastatin calcium; periodontitis; gel; Carbopol 934

Academic Editor(s): Name

Published: date



Copyright: © 2023 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Chronic periodontitis (CP) is a condition of inflammation with a microbial origin that predominantly affects the tissues that support the teeth and causes the periodontal ligament and alveolar bone to gradually deteriorate [1]. Statins influence the inflammatory response, immunological response, bone metabolism, and bacterial clearance through several different routes. They primarily achieve this through the ERK, MAPK, PI3-Akt, and NF-κB pathways, which promote the production of anti-inflammatory and/or pro-resolution molecules while inhibiting the release of proinflammatory cytokines. Additionally, they can control the host reaction brought on by the bacterial challenge, stop inflammation-mediated bone resorption, and encourage bone growth [2].

Atorvastatin Calcium (ATV) is highly known for its anti-hyperlipidemic activity, but according to several studies, it has also proved to have good anti-inflammatory properties

against periodontitis, along with improving bone density [3,4]. Furthermore, they prevent the disease from getting worse by reducing bacterial growth, compromising the stability of bacterial membranes, and enhancing bacterial clearance. In comparison to systemic delivery, local statin administration as an adjuvant to both nonsurgical and surgical periodontal therapy leads to superior periodontal treatment outcomes [5]. According to several clinical studies like [3,4], and [6] Atorvastatin Calcium (ATV) has proved to have good anti-inflammatory properties for periodontal disease.

Niosomes are a vesicular, new drug delivery technology that can be employed for prolonged, regulated, and targeted drug administration. Because niosomes are composed of non-ionic surfactants and cholesterol, they are non-toxic as a result of these surfactants. Niosomes are self-assembling vesicles made up of non-ionic surfactants in which the drug is encapsulated. The main feature of niosomes is that it contains a polar head and a hydrophobic tail. They self-assemble by forming two domains by external energy like heat, agitation, or both. It has an aqueous center and a lipophilic domain which is formed due to the hydrophobic tail. Due to their structure, they can be used to load and distribute hydrophilic and hydrophobic drugs. Niosomes can help increase the oral bioavailability of poorly soluble drugs, in this case, Atorvastatin Calcium [5–10].

A niosomal gel will help with patient compliance and can prevent problems with gastrointestinal drug absorption brought on by stomach pH. Also, gels can prevent drug interactions and enzymatic activity with meals and beverages. When the oral route is inappropriate, local oral administration of drugs in the form of gel can increase compliance [11].

This study aims to develop and evaluate a niosomal gel containing Atorvastatin Calcium for periodontitis, by studying the ability of Atorvastatin Calcium to aid periodontitis. Oral gel formulations will aid in patient compliance by providing easy application and potentially providing targeted and localized treatment to the affected areas. Dental oral gels can be used in conjunction with professional dental treatments such as scaling and root planing (deep cleaning).

2. Materials and Methods

Atorvastatin Calcium was received as a gift sample from Micro Labs Pvt. Ltd., Mumbai, Maharashtra, India. Cholesterol, Tween 80, Span 60, Carbopol 934, Dichloromethane, Triethanolamine, and Propylene glycol were purchased from Research-Lab Fine Chem Industries, Mumbai, Maharashtra, India.

2.1. Preparation of Niosomes Loaded with Atorvastatin Calcium

The process of thin-film hydration (Figure 1), also known as the Hand-Shaking method, is frequently used to prepare niosomes. The drug, non-ionic surfactant, and cholesterol are combined with an organic solvent, here dichloromethane, in a round bottom flask to make niosomes in this manner. A rotating vacuum evaporator (Superfit Rotavap-PBU 6D) is then used to evaporate the organic solvent. A thin layer develops on the interior surface of the round-bottom flask during evaporation. The thin layer is then hydrated at a temperature greater than the surfactant's transition temperature. In this case, a Phosphate Buffer Solution (PBS) of pH 7.4 was used for hydration. Hydration causes the layer to swell and the drug-containing vesicles to form [11–14]. Different concentrations of cholesterol and non-ionic surfactant were used to prepare different batches of niosomes (Table 1).

Table 1. Formulation table for ATV niosomal formulations.

Formulation	Drug (mg)	Cholesterol (mg)	Span 60 (mg)	Tween 80 (mg)
NF1	200	100	100	-
NF2	200	100	200	-
NF3	200	200	100	-

NF4	200	50	50	-
NF5	200	50	100	-
NF6	200	100	50	-
NF7	200	100	-	100
NF8	200	50	-	50
NF9	200	100	-	200
NF10	200	200	-	100
NF11	200	100	-	300
NF12	200	300	-	100

The prepared niosomes were optimized using parameters such as entrapment efficiency (EE), TEM analysis, polydispersity index, and zeta potential. An optimized niosomal formulation was used for further characterization [15,16].




Figure 1. Schematic representation of thin film hydration method.

2.2. Preparation of Nanogel Loaded with Atorvastatin Calcium Niosomes

- Gel was prepared using the dispersion method, Carbopol 934 was progressively introduced into distilled water to fully hydrate and allowed to stay for 24 h. For the niosomal gel, the optimized loaded niosome was gradually added to the hydrated Carbopol 934 on a magnetic stirrer (REMI 1MLH), along with propylene glycol resulting in a final concentration of 1.2% (*w/w*) of Atorvastatin Calcium niosomal gel. The produced gel's pH was then measured and adjusted to pH 6–7 using triethanolamine and the final weight was adjusted using distilled water. Various batches of gel were prepared (Table 2), by varying the Carbopol concentration (0.5%–2.0%) [17,18].

Table 2. Formulation table of Atorvastatin Calcium loaded niosomal gel.

Formulation Code	Carbopol 934 (%)	Propylene Glycol (%)
NF1G1	0.5	10
NF1G2	1.0	10
NF1G3	1.5	10
NF1G4	2.0	10

- The optimized niosomal gel was evaluated for homogeneity, grittiness, pH, viscosity, spreadability, extrudability, drug content, drug deposition, and in-vitro studies [17–19], and an anti-microbial study was conducted against *S. aureus* and *P. aeruginosa* by using the agar well diffusion method [20,21].

2.3. Determination of %Entrapment Efficiency of ATV-Niosomes

The amount of Atorvastatin Calcium entrapped in niosomes was determined by the indirect method using centrifugation. 5 mL of niosomal suspension was placed in a centrifugation tube and centrifuged at 10,000 RPM for 10 min at 4 °C. The entrapped amount of Atorvastatin Calcium in niosomes was determined after separating non-entrapped drug from the supernatant. 1ml of supernatant was dissolved in methanol and serial dilutions followed by filtration was done and the prepared dilutions were analyzed spectrophotometrically using a UV-Vis Double beam spectrophotometer at 244 nm. Entrapment

efficiency is stated as the percent of drug trapped in the vesicle. It is determined by following Equation (1) [15].

$$\% \text{ Entrapment efficiency} = \frac{\text{Amount of drug added} - \text{Amount of drug in supernatant}}{\text{Total amount of drug added}} \times 100 \quad (1)$$

2.4. Drug Content of ATV-Niosomal Nanogel

1 gm of each gel preparation was dissolved in methanol (10 mL) using bath sonication. This sample was then subjected to centrifugation. 1 mL from the supernatant was used for serial dilutions to create different concentrations. Following filtration, absorbances were measured at 244 nm. Drug content was determined using the calibration curve and the linearity equation [22].

2.5. Drug Deposition Study of ATV-Niosomal Nanogel

The drug deposited on the oral mucosa was calculated. After a 24-h diffusion study, the oral mucosal membrane was taken out and carefully washed with distilled water for 10 s to remove the gel formulation that had adhered to it. The drug was then removed from the mucosa by sonicating it for 30 min in 10 mL of methanol. Suitable dilutions were carried out following filtration. The amount of Atorvastatin Calcium was then measured spectrophotometrically in methanol using UV-Vis Spectrophotometer [23].

3. Results and Discussion

UV spectrophotometry was used for the determination of λ_{\max} and the plotting of the calibration curve of the drug in methanol and in phosphate buffer pH 7.4. The compatibility between the drug and the excipients was evaluated using the FTIR method, which showed no interaction between the excipients and the drug (Figure 2).




Figure 2. FTIR Spectra for ATV-niosomal gel.

3.1. Characterization of Niosomes Loaded with Atorvastatin Calcium

3.1.1. Entrapment Efficiency

The entrapment efficiency was in the range of 84–42%, with NF1 having the maximum entrapment efficiency of $84.18 \pm 1.45\%$.

3.1.2. Transmission Electron Microscopy (TEM)

TEM image (Figure 3) of niosomal vesicles shows particle size 100–300 nm.




Figure 3. TEM image of niosomal vesicles.

3.1.3. Zeta Potential

The Zeta potential of the NF1 formulation was calculated using a Malvern Zeta-sizer. The niosomes' Zeta potential was discovered to be -18.7 ± 5.46 mV (Figure 4a), indicating that the formulation was stable.

3.1.4. Size Distribution and Polydispersity Index (PDI)

The average size of the niosome was found to be 234 ± 37.8 d. nm and the PDI was found to be 0.106 (Figure 4b).




Figure 4. (a) Zeta Potential, and (b) Particle size, and PDI of optimized niosomal gel.

3.2. Characterization of Nanogel Loaded with Atorvastatin Calcium Niosomes

3.2.1. Homogeneity and Grittiness

The homogeneity and grittiness of NF1G2 were better than the other formulation; under an optical microscope, no apparent particulate matter was found in NF1G2. As a result, it meets the criteria of being free of particle matter.

3.2.2. pH determination

The pH of all formulated gels was found to be in the range of pH 7.1–7.4, indicating all formulations to be near neutral pH (Table 3).

3.2.3. Viscosity

The viscosity of the niosomal gel was evaluated using a Brookfield viscometer (DV2T model) with a Helipath spindle T series (D94). NF1G2 showed appropriate viscosity as compared to NF1G1, which was less viscous, and NF1G3 and NF1G4, which were highly viscous (Table 3).

3.2.4. Spreadability

The term spreadability refers to how quickly the gel spreads when a small amount of shear is applied. The spreadability of NF1G1 and NF1G2 was found to be better (Table 3).

3.2.5. Extrudability

The amount of gel that is extruded through the tube's opening when pressure is applied was used to gauge extrudability. The extrudability of NF1G2 gel was found to be better as compared to other formulations (Table 3).

3.2.6. Drug Content

The drug content of NF1G2 was found to be the highest ($86.13 \pm 6.31\%$) as compared to other gel prepared. The drug content was found to be in the range of 69% to 86% (Table 3).

3.2.7. Drug Deposition

The amount of drug deposited after 24 h of diffusion on the oral mucosal layer was found to be lowest for NF1G2, i.e., $17.23 \pm 3.52\%$, indicating that $82.77 \pm 5.49\%$ of the drug was released during the diffusion. Thus, concluding that NF1G2 is better than other formulations.

Table 3. Results of evaluation of ATV-niosomal gel.

Formulation	pH	Viscosity (cP)	Spreadability (g.cm/sec)	Extrudability (%)	Drug Content (%)	Drug deposition (%)
NF1G1	7.33	20,430 \pm 361	130.45 \pm 6.31	93.7 \pm 2.98	78.08 \pm 5.61	21.93 \pm 2.27
NF1G2	7.45	25,410 \pm 437	115.46 \pm 4.23	91.2 \pm 5.81	86.83 \pm 6.31	17.23 \pm 3.52
NF1G3	7.12	37,428 \pm 579	75.25 \pm 3.78	87.8 \pm 4.73	74.24 \pm 2.11	25.64 \pm 3.82
NF1G4	7.29	45,672 \pm 683	56.25 \pm 2.16	84.4 \pm 3.21	69.1 \pm 1.98	37.47 \pm 4.89

3.2.8. Anti-Microbial Study

Antimicrobial activity was estimated by measuring the zone of inhibition of the optimized niosomal gel (NF1G2) against *S. aureus* (ATCC 6538) and *P. aeruginosa* (ATCC 27853), which are also responsible factors for periodontitis and were procured from NCIM. The zone of inhibition for *S. aureus* of pure Atorvastatin Calcium and ATV-niosomal gel was found to be 11 ± 0.16 mm (Figure 5a) and 28 ± 0.48 mm (Figure 5c), respectively, and the zone of inhibition for *P. aeruginosa* of pure Atorvastatin Calcium and ATV-niosomal gel was found to be 16 ± 0.27 mm (Figure 5b) and 25 ± 0.34 mm (Figure 5d), respectively, indicating that gel works more effectively than pure Atorvastatin Calcium.




Figure 5. In-vitro Antimicrobial Activity; (a) *S. aureus* (ATV), (b) *P. aeruginosa* (ATV), (c) *S. aureus* (Niosomal gel), (d) *P. aeruginosa* (Niosomal gel).

3.2.9. In-Vitro Diffusion and Kinetic Modelling

The NF1G2 formulation showed maximum drug diffusion up to $83.04 \pm 6.04\%$ at 7 h. The kinetic studies interpret that the NF1G2 formulation follows a zero-order model (Figure 6).



Figure 6. Zero Model Kinetic Model of optimized ATV-niosomal gel.

3.2.10. Stability Studies

The optimized niosomal gel formulation (NF1G2) was stored at 40 ± 2 °C and 75% RH in a stability chamber for 90 days. The sample was withdrawn periodically and evaluated for pH, % drug content, and in-vitro drug diffusion was found to be optimum and satisfactory and there was no significant change in the formulation (Figure 7).




Figure 7. Stability Studies of optimized ATV-niosomal gel.

4. Conclusions

The ATV-niosome showed the highest entrapment efficiency, up to $84.18 \pm 1.45\%$. The niosomes' zeta potential was -18.7 ± 5.46 mV and its PDI was 0.106, indicating that the formulation was stable. The drug content of the niosomal gel was found to be $86.65 \pm 6.31\%$. The desired results were obtained with 1% Carbopol 934 niosomal gel, which demonstrated in-vitro release for up to 7 h and followed a zero-order kinetic model. Anti-microbial activity against strains like *S.aureus* and *P. aeruginosa*, which contribute to periodontitis, indicates that ATV-niosomal gel can be used for inflammatory periodontal conditions. The niosomal formulation may be more successful than other conventional formulations used in periodontal problems, as it may reduce symptoms faster and has enormous potential for future therapeutic applications.

Author Contributions: Conceptualization, B.R.R. and N.S.K.; methodology, B.R.R. and N.S.K.; software, B.R.R. and N.S.K.; formal analysis, B.R.R. and N.S.K.; investigation, B.R.R. and N.S.K.; resources, B.R.R. and A.S.J.; data curation, N.S.K. and B.R.R.; writing—original draft preparation, B.R.R. and N.S.K.; writing—review and editing, N.S.K., B.R.R. and A.S.J.; visualization, B.R.R. and

A.S.J.; supervision, B.R.R.; funding acquisition, A.S.J. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: This work is supported and fortified by Shri D.D. Vispute College of Pharmacy and Research Center, Panvel, India.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Shirke, P.Y.; Kolte, A.P.; Kolte, R.A.; Bawanakar, P.V. Evaluation of the Clinical Efficacy of 1.2% Atorvastatin in the Treatment of Periodontal Intraosseous Defects by CBCT: A Randomized Controlled Clinical Trial. *J. Dent. Res. Dent. Clin. Dent. Prospects* **2019**, *13*, 183–191. <https://doi.org/10.15171/joddd.2019.029>.
2. Petit, C.; Batool, F.; Bugueno, I.M.; Schwinté, P.; Benkirane-Jessel, N.; Huck, O. Contribution of Statins towards Periodontal Treatment: A Review. *Mediators Inflamm.* **2019**, *2019*, 6367402. <https://doi.org/10.1155/2019/6367402>.
3. Martande, S.S.; Kumari, M.; Pradeep, A.R.; Pal Singh, S.; Kumar Suke, D. Comparative Evaluation of Efficacy of Sub gingivally Delivered 1.2% Atorvastatin and 1.2% Simvastatin in the Treatment of Intraosseous Defects in Chronic Periodontitis: A Randomized Controlled Trial. *J. Dent. Res. Dent. Clin. Dent. Prospects* **2017**, *11*, 18–25. <https://doi.org/10.15171/joddd.2017.004>.
4. Kumari, M.; Martande, S.S.; Pradeep, A.R.; Naik, S.B. Efficacy of Sub gingivally Delivered 1.2% Atorvastatin in the Treatment of Chronic Periodontitis in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Clinical Trial. *J. Periodontol.* **2016**, *87*, 1278–1285. <https://doi.org/10.1902/jop.2016.130227>.
5. Tahamtan, S.; Shirban, F.; Bagherniya, M.; Johnston, T.P.; Sahebkar, A. The Effects of Statins on Dental and Oral Health: A Review of Preclinical and Clinical Studies. *J. Transl. Med.* **2020**, *18*, 155. <https://doi.org/10.1186/s12967-020-02326-8>.
6. Pradeep, A.R.; Kumari, M.; Rao, N.S.; Martande, S.S.; Naik, S.B. Clinical Efficacy of Sub gingivally Delivered 1.2% Atorvastatin in Chronic Periodontitis: A Randomized Controlled Clinical Trial. *J. Periodontol.* **2013**, *84*, 871–879. <https://doi.org/10.1902/jop.2012.120393>.
7. Bhardwaj, P.; Tripathi, P.; Gupta, R.; Pandey, S. Niosomes: A Review on Niosomal Research in the Last Decade. *J. Drug Deliv. Sci. Technol.* **2020**, *56*, 101581. <https://doi.org/10.1016/j.jddst.2020.101581>.
8. Sharma, R.; Due, J.S.; Parsed, D.N. An Overview on Niosomes: Novel Pharmaceutical Drug Delivery System. *J. Drug Deliv. Ther.* **2022**, *12*, 171–177. <https://doi.org/10.22270/jddt.v12i2-s.5264>.
9. Madame, V.B.; Mokale, V.J. Niosomes as an Ideal Drug Delivery System. *J. NanoSci. Res. Rep.* **2021**, *3*, 1–9. <https://doi.org/10.47363/jnsrr/2021123>.
10. Akbarzadeh, I.; Sedaghatnia, K.; Bourbour, M.; Moghaddam, Z.; Moghtaderi, M.; Samimi-Sohrforozani, E.; Quazi, S.; Far, B. Niosomes: A Novel Targeted Drug Delivery System. *Preprints*, **2021**, 2021120315. <https://doi.org/10.20944/preprints202112.0315.v1>.
11. Suchithra, A.B.; Jeganath, S.; Jeevitha, E. Pharmaceutical Gels, and Recent Trends—A Review. *Res. J. Pharm. Technol.* **2019**, *12*, 6181. <https://doi.org/10.5958/0974-360x.2019.01073.4>.
12. Kauslya, A.; Borawake, P.D.; Shinde, J.V.; Chavan, R.S. Niosomes: A Novel Carrier Drug Delivery System. *J. Drug Deliv. Ther.* **2021**, *11*, 162–170. <https://doi.org/10.22270/jddt.v11i1.4479>.
13. Bakliwal, S.R.; Rane, B.R.; Jain, A.S. Niosomes and Proniosomes. In *A Glimpse of Novel Vesicular Drug Delivery Systems*; Nirali Prakashan: Pune, India, 2017; pp 4.1–4.10.
14. Ge, X.; Wei, M.; He, S.; Yuan, W.-E. Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery. *Pharmaceutics* **2019**, *11*, 55. <https://doi.org/10.3390/pharmaceutics11020055>.
15. Shirisha, N.; Fazal UI Haq, S. Formulation and Evaluation of Mefenamic Acid Niosomal Gel. *Res. Rev. J. Pharm. Nanotechnol.* **2022**, *10*, 1–10.
16. Kamboj, S.; Saini, V.; Bala, S. Formulation and characterization of drug-loaded nonionic surfactant vesicles (niosomes) for oral bioavailability enhancement. *Sci. World J.* **2014**, *2014*, 959741. <https://doi.org/10.1155/2014/959741>.
17. Rane, S.; Inamdar, Y.; Rane, B.; Jain, A. Niosomes: A Non-Ionic Surfactant Based Vesicles as a Carriers for Drug Delivery. *Int. J. Pharm. Sci. Rev. Res.* **2018**, *51*, 198–213.
18. Zaid Alkilani, A.; Hamed, R.; Abdo, H.; Swellmeen, L.; Basheer, H.A.; Wahdan, W.; Abu Kwiak, A.D. Formulation and Evaluation of Azithromycin-Loaded Niosomal Gel: Optimization, in Vitro Studies, Rheological Characterization, and Cytotoxicity Study. *ACS Omega* **2022**, *7*, 39782–39793. <https://doi.org/10.1021/acsomega.2c03762>.
19. Dubey, A. Niosomal Gel of Adapalene: Its Formulation, Physicochemical Properties, and Evaluation for Mild-Acne. *Adv. Bio-med. Pharm.* **2015**, *2*, 22–31. <https://doi.org/10.19046/abp.v02i01.04>.

20. Balouiri, M.; Sadiki, M.; Ibsouda, S.K. Methods for in Vitro Evaluating Antimicrobial Activity: A Review. *J. Pharm. Anal.* **2016**, *6*, 71–79. <https://doi.org/10.1016/j.jpha.2015.11.005>.
21. Nalawade, T.M.; Bhat, K.G.; Sogi, S. Antimicrobial Activity of Endodontic Medicaments and Vehicles Using Agar Well Diffusion Method on Facultative and Obligate Anaerobes. *Int. J. Clin. Pediatr. Dent.* **2016**, *9*, 335–341. <https://doi.org/10.5005/jp-journals-10005-1388>.
22. Jain, D.V.; Lovanshi, R.; Khan, A.I. Formulation Development and Evaluation of Niosomal Gel of Tazarotene for Treatment of Psoriasis. *J. Med. Pharm. Allied Sci.* **2021**, *10*, 2664–2670.
23. Abdelbary, G.A.; Aburahma, M.H. Oro-Dental Mucoadhesive Proniosomal Gel Formulation Loaded with Lornoxicam for Management of Dental Pain. *J. Liposome Res.* **2015**, *25*, 107–121. <https://doi.org/10.3109/08982104.2014.941861>.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.